SEC Filing Summary
Filing entity and period: The source filing is for Landec Corporation (NASDAQ: LNDC), not Lifecore Biomedical, Inc. It reports the fiscal quarter ended August 28, 2022, which is fiscal first quarter 2023. The requested metadata identifies “Lifecore Biomedical” and “2021 Q3,” so the filing-period and entity match should be verified.
Business Context
Landec operates through Lifecore, a pharmaceutical contract development and manufacturing organization, and Curation Foods, which sells avocado products and olive oils and vinegars. The company completed the sale of its Eat Smart business in December 2021 and sold its BreatheWay technology business in June 2022. Management stated that it intended to continue exploring sales of the remaining Curation Foods assets, including Yucatan Foods and O Olive, with anticipated completion during fiscal 2023, subject to market conditions.
Financial Performance
| Metric | Q1 FY2023 | Q1 FY2022 | Change |
|---|---|---|---|
| Revenue | $43.4 million | $41.6 million | Up 4% |
| Gross profit | $5.8 million | $10.4 million | Down 44% |
| Gross margin | 13.4% | 25.1% | Down 11.7 points |
| Operating loss | $8.2 million | $2.7 million | Loss increased |
| Net loss from continuing operations | $12.1 million | $7.6 million | Loss increased |
| Net loss | $12.1 million | $9.5 million | Loss increased |
| Basic and diluted loss per share | $0.41 | $0.32 | Loss per share increased |
| Net cash from operating activities | $(1.5) million | $0.8 million | Declined $2.4 million |
Lifecore revenue increased 8% to $23.7 million, including higher fermentation and development-services revenue. Lifecore gross profit increased 6% to $6.1 million. Curation Foods revenue was essentially flat at $19.7 million, but its gross profit declined to a $0.3 million loss from $4.7 million of profit, primarily because of higher freight and raw-material sourcing costs.
Total operating costs were $14.0 million, including $2.0 million of research and development, $10.9 million of selling, general and administrative expense, and $1.0 million of restructuring costs. SG&A increased 15%, driven primarily by higher legal fees related to compliance and litigation matters and higher Curation Foods compensation costs.
Cash, Debt and Liquidity
- Cash and cash equivalents were $4.2 million at August 28, 2022, up from $1.6 million at May 29, 2022.
- Current assets were $116.6 million and current liabilities were $83.1 million, implying a current ratio of approximately 1.4x.
- Accounts receivable were $40.9 million and inventories were $64.3 million.
- The company had $44.0 million outstanding under its revolving credit facility and $103.7 million of term-loan principal. Debt carrying value, including the revolver and net term debt, was approximately $142.6 million.
- The revolver bore interest at 4.1% and the term loan at 10.1% at quarter-end. The facilities are secured by substantially all company and subsidiary assets and mature in 2025.
- Cash provided by investing activities was $0.2 million, reflecting $3.1 million of proceeds from the BreatheWay sale offset by $2.9 million of capital expenditures.
- Cash provided by financing activities was $3.9 million, primarily from a $4.0 million increase in borrowings under the line of credit.
- Management stated that the company was in compliance with all financial covenants and had no debt-default events as of August 28, 2022.
Material Changes and Unusual Items
- Revenue grew modestly, but gross profit fell sharply because of Curation Foods cost inflation and freight pressure.
- The company recorded a $2.1 million gain on the sale of BreatheWay assets, included in SG&A.
- Restructuring costs were $1.0 million, compared with $1.8 million in the prior-year quarter. Total expected restructuring costs under the plan were approximately $23.0 million.
- Interest expense declined to $3.7 million from $6.7 million because the prior-year period included interest and prepayment penalties associated with debt repayments funded by asset-sale proceeds.
- The prior-year quarter included a $1.8 million loss from discontinued Eat Smart operations; no discontinued-operation loss was reported in the current quarter.
- The company sold BreatheWay and stated that it was preparing for a transition toward a Lifecore-focused business.
Outlook, Risks and Contingencies
The filing does not provide formal quantitative earnings or revenue guidance. Management cautioned that results may fluctuate because of Curation Foods seasonality and Lifecore customer order patterns.
- Management identified risks from COVID-19, adverse economic conditions, regulatory approvals, customer acceptance of new products, weather-related produce costs, supply-chain conditions and the mix of domestic and international sales.
- The company remains subject to SEC, Department of Justice, Mexican government and regulatory investigations involving potential environmental and Foreign Corrupt Practices Act matters related to its Tanok facility. The ultimate outcome, timing and financial impact are uncertain, and no recovery asset was recorded.
- A former Yucatan owner seeks more than $10 million in damages; Landec has asserted counterclaims seeking at least $80 million. The filing states that outcomes and potential net losses cannot presently be estimated.
- Disclosure controls were considered ineffective at quarter-end because of a previously reported material weakness involving the completeness and accuracy of accounting for non-standard transactions, including discontinued operations and restructuring activity. Remediation had begun but was not complete.
- Two customers accounted for 16% and 10% of quarterly revenue. Three customers represented 21%, 16% and 13% of accounts receivable at quarter-end.
Important Facts for Investors to Verify
- Confirm the correct issuer and period: the filing is Landec Corporation’s August 28, 2022 Form 10-Q, not a Lifecore Biomedical standalone filing or a 2021 third-quarter filing.
- Assess whether Lifecore’s revenue growth and capital investments can offset Curation Foods’ negative gross profit and corporate costs.
- Review liquidity, debt maturities, variable interest exposure and the company’s ability to fund operations while carrying approximately $142.6 million of debt.
- Track progress and costs related to the planned sale of the remaining Curation Foods assets.
- Monitor the Tanok compliance investigations, related litigation and possible indemnification recoveries.
- Verify remediation of the material weakness and whether disclosure controls are subsequently reported as effective.